Business
Par Health Names Dr. William Larkins as EVP and Chief Scientific Officer and President, Sterile Injectables
Par Health, Inc. ("Par Health" or the "Company") today announced the appointment of Dr. William ("Bill") Larkins as Executive Vice President and Chief Scientific Officer and President, Sterile Injectables.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"Appointment Enhances Leadership Team with Deep Sterile Injectables Expertise and Ability to Drive the Company's Global R&D Strategy and Execution","length":153,"tagName":"p","attribs":{}},{"type":"text","content":"ST. LOUIS, Jan. 12, 2026 /PRNewswire/ -- Par Health, Inc. ("Par Health" or the "Company") today announced the appointment of Dr. William ("Bill") Larkins as Executive Vice President and Chief Scientific Officer and President, Sterile Injectables.","length":281,"tagName":"p"},{"type":"image","alt":"Par Health logo (PRNewsfoto/Par Health)","displaySize":"","headline":null,"caption":"Par Health logo (PRNewsfoto/Par Health)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":176,"url":"https://media.zenfs.com/en/prnewswire.com/696f8592fbc1f144d0aabea523604140"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ojOSYUt4AVruhdTOLQYCHw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMxMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/696f8592fbc1f144d0aabea523604140","width":400,"height":176}},"href":"https://mma.prnewswire.com/media/2818021/Par_Health_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Larkins brings more than 30 years of experience in sterile injectables, positioning him as the ideal candidate to lead the turnaround of Par Health's sterile injectables segment. From September 2023 through the end of 2025, he served as President, Global Injectables for Hikma Pharmaceuticals, where he drove strong revenue growth in all regions and launched hundreds of new products. In addition to his role as President, Dr. Larkins oversaw R&D and Regulatory Affairs for the Global Injectables Unit, leading innovation, pipeline and product approvals.","length":566,"tagName":"p"},{"type":"text","content":"He joined Hikma in 2022 as Senior Vice President of R&D for Injectables following its acquisition of Custopharm, Inc., where he served as Chief Executive Officer for eight years. Throughout his distinguished career, Dr. Larkins has held senior leadership roles at leading pharmaceutical companies, including Bedford Laboratories, Amylin Pharmaceuticals, Sandoz, ESI Lederle/Baxter and Barr Laboratories.","length":407,"tagName":"p"},{"type":"text","content":""We are thrilled to welcome Bill to Par Health, where he will ...